Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3337 - 3344 of 12089 results
For New Mintz Partner, A Push to Promote Women in Communications
March 26, 2021| News
CBD Regulatory Enforcement Continues with Over-the-Counter CBD Pain Relief Products
March 25, 2021| Blog| Viewpoint
USPTO Provides Guidance on Conducting an Effective Patent Examiner Interview
March 25, 2021| Blog| Viewpoint
The Beauty and the Terror of Agile Software Development
March 24, 2021| Advisory| Viewpoint
Obviousness-Type Double Patenting and Divisional Applications in Canada
March 23, 2021| Blog| Viewpoint
Senate Confirms Walsh as Labor Secretary; Janey Becomes Acting Boston Mayor
March 23, 2021| News
Fifth Circuit Finds Flaws in CPSC Rulemaking on Phthalate Limits Highlighting Another Rulemaking Misstep for the Agency
March 22, 2021| Blog| Viewpoint
Not So Fast: DOL Changes Course on Trump-Era ESG Investment Rule
March 22, 2021| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|